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AbstrACt
Introduction The intake of polyphenols has certain health 
benefits. This study will aim to assess the effect of adding 
a daily amount of chocolate high in cocoa content and 
polyphenols to the normal diet on blood pressure, vascular 
function, cognitive performance, quality of life and body 
composition in postmenopausal women.
Methods and analysis Here we plan a randomised 
clinical trial with two parallel groups involving a 
total of 140 women between 50 and 64 years in the 
postmenopausal period, defined by amenorrhoea of  at 
least 12 consecutive months. The main variable will be 
the change in blood pressure. Secondary variables will 
be changes in vascular function, quality of life, cognitive 
performance and body composition. The intervention 
group will be given chocolate containing 99% cocoa, with 
instructions to add 10 g daily to their normal diet for 6 
months. The daily nutritional contribution of this amount 
of chocolate is 59 kcal and 65.4 mg of polyphenols. There 
will be no intervention in the control group. All variables 
will be measured at the baseline visit and 3 and 6 months 
after randomisation, except cognitive performance and 
quality of life, which will only be assessed at baseline and 
at 6 months. Recruitment is scheduled to begin on 1 June 
2018, and the study will continue until 31 May 2019.
Ethics and dissemination This study was approved 
by the Clinical Research Ethics Committee of the Health 
Area of Salamanca, Spain (‘CREC of Health Area of 
Salamanca’), in February 2018. A SPIRIT checklist is 
available for this protocol. The clinical trial has been 
registered at  ClinicalTrials. gov provided by the US National 
Library of Medicine, number NCT03492983. The results 
will be disseminated through open access peer-reviewed 
journals, conference presentations, broadcast media and a 
presentation to stakeholders.
IntroduCtIon 
Polyphenols are bioactive compounds found 
in many plants, fruits and vegetables. The 
beneficial effects on human health associ-
ated with the consumption of a diet rich in 
polyphenols have generated great scientific 
interest in these substances.1–3 The action 
of polyphenols is based on their antioxidant 
capacity through the uptake of free radicals, 
the chelation of metals with redox properties 
and the modulation and inhibition of enzy-
matic activities.4 
The most abundant polyphenols in cocoa 
are flavonoids, which have been linked to 
a protective effect against cardiovascular 
disease, decreasing the risk of cardiovascular 
morbidity and mortality and favouring the 
prevention of other chronic diseases, such 
as diabetes mellitus type 2.1–3 5–7 The ability 
to reduce cardiovascular risk could be due to 
an improvement in the elements that define 
metabolic syndrome, the improvement of 
vascular endothelial dysfunction, insulin 
resistance and the inhibition of platelet acti-
vation and aggregation.8 9 However, although 
current evidence suggests that polyphenols 
produce an improvement in cardiovascular 
health, this is insufficient to determine the 
minimum amount of intake necessary to 
achieve health benefits.10
strengths and limitations of this study
 ► This study will use commercially available chocolate 
with a high content of cocoa and polyphenols during 
the intervention.
 ► Blood pressure and vascular function will be mea-
sured objectively using a sphygmomanometer and 
a Vasera VS-2000 device (Fukuda Denshi), with 
body composition measured by impedance analysis, 
while the quality of life and cognitive performance 
will be assessed using validated instruments.
 ► Due to the nature of the intervention, the partici-
pants cannot be blinded, although the researchers 
who perform the measurements and the statistical 
analysis will be blinded.
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Cocoa polyphenols and blood pressure
The effect of consuming polyphenols present in choco-
late on the blood pressure statistics of healthy individuals 
is unclear. Cocoa consumption has been associated with 
an improvement in endothelial function and a decrease 
in blood pressure in both healthy subjects and those with 
risk factors and cardiovascular diseases.11 12 Some studies 
have observed a dose-dependent relationship between 
cocoa intake and clinical blood pressure, with higher 
consumption equated to lower blood pressure and better 
vascular function.13 14 Conversely, other research has not 
obtained significant changes in these parameters related 
to the supplementation of cocoa or pure polyphenols, 
such as epicatechin or quercetin.15 16
Endothelial dysfunction in postmenopausal women 
causes changes that favour the development of cardio-
vascular risk factors and atherosclerosis, which lead to 
the appearance and maintenance of hypertension.17 18 
A decrease in blood pressure has been observed in this 
group after daily consumption of cocoa with a flavonol 
content of 40.12 mg. Below this level, however, no changes 
have been observed.19
Cocoa polyphenols and vascular function
Among healthy individuals, as well as postmenopausal 
women, the consumption of polyphenols present in cocoa 
has been associated with a dose-dependent improve-
ment of vascular function, in particular of arterial stiff-
ness measured by pulse wave speed.13 14 19 One of these 
studies also suggests that the reduction in arterial stiffness 
observed in postmenopausal women after consumption 
of cocoa is independent of the frequency of the intake.19 
However, this relationship is not evident in people with 
mild hypertension when cardio-ankle vascular index 
(CAVI) is used as a measure of arterial stiffness.20
There is also evidence of the influence of these poly-
phenols in reducing the augmentation index (AIx). The 
study by West et al,21 involving subjects with excess weight 
and moderate obesity, concludes that treatment with dark 
chocolate decreases AIx in women, although it seems 
that this association might have a greater effect on the 
elasticity of the large arteries, especially in subjects with 
obesity and diabetes mellitus type 2.22
Cocoa polyphenols and cognitive performance
There is evidence to suggest that chocolate rich in poly-
phenols is beneficial for cognitive performance and state 
since it improves mental processing speed and attenu-
ates the increase of mental fatigue among healthy young 
adults.23 24 An improvement in cognitive performance 
among older age groups after eating chocolate has also 
been observed,25 especially in subjects with higher risk 
of cardiovascular disease.26 Several studies also show 
that polyphenol-rich chocolate causes an improvement 
in executive function, categorical fluency27 and working 
memory,28 29 and a slowing of mental fatigue.30 Also, a 
higher frequency of chocolate consumption has been asso-
ciated with improved cognitive function.29 Furthermore, 
a positive influence of cocoa polyphenols on physiolog-
ical processes has been reported, with a neuroprotec-
tive effect31 and improved cognitive performance.32 In 
this regard, it has been suggested that the brain-derived 
neurotrophic factor plays a role in the cognitive enhance-
ment induced by the flavonoides.33 Favourable effects on 
cerebrovascular function have also been observed in post-
menopausal women after consumption of chocolate with 
a high concentration of cocoa.34
Cocoa polyphenols and quality of life
The quality of life linked to health is represented by the 
individual’s perception of well-being in various aspects 
of life, including physical and mental aspects. The effect 
of chocolate and polyphenols on the quality of life has 
scarcely been studied, with little available evidence and 
even less of a conclusive nature. In a study conducted 
among healthy people, where regular consumption 
of chocolate was recorded over 1 year, no evidence was 
found of a clear association between chocolate intake and 
the physical or mental components of quality of life.35 
Nevertheless, it has been observed that the consumption 
of dark chocolate might be beneficial for the quality of 
life of women with fibromyalgia.36
Cocoa polyphenols and body composition
The menopause period leads to various changes in the 
body composition of women.37 Regarding the connection 
between cocoa polyphenols and body composition, results 
diverge. Some clinical trials involving healthy people and 
overweight or obese patients have not reported signif-
icant differences that link chocolate consumption to 
anthropometric measures.16 20 21 38 Other studies indicate 
that chocolate consumption might have positive effects 
on body composition in adolescents,39patients with 
diabetes40 or women with obesity.41 Two recent systematic 
reviews also indicate that eating chocolate is associated 
with reduced body mass index (BMI) and waist circumfer-
ence,42 43 and one of them also concludes that the amount 
and the length of time during which it is eaten play a key 
role in these beneficial effects.43 Conversely, other studies 
such as that carried out with the cohort of the Athero-
sclerosis Risk in Communities study have observed a 
dose-dependent increase in weight after habitual choco-
late consumption.44
In sum, the polyphenols present in chocolate seem to 
have a positive effect on blood pressure, vascular func-
tion, cognitive performance and quality of life, especially 
in populations with increased cardiovascular risk, such 
as postmenopausal women.45 However, the conflicting 
results obtained in different studies suggest that the 
real contribution of these compounds to health and the 
underlying mechanisms remain unclear. Moreover, most 
of these studies have used preparations with high concen-
trations of polyphenols that are usually not present in the 
normal diet.
This study aims to evaluate the effect of adding a daily 
amount of 10 g of chocolate high in cocoa content (99%) 
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and polyphenols to the normal diet on blood pressure, 
vascular function, cognitive performance, quality of life 
and body composition in postmenopausal women.
MEthods And AnAlysIs
design and setting
This controlled and randomised clinical trial involves 
two parallel groups. The study will be carried out in the 
Research Unit of the La Alamedilla Health Centre in Sala-
manca (Spain), which is part of the Biomedical Research 
Institute of Salamanca and the Primary Care Prevention 
and Health Promotion Research Network. The recruit-
ment schedule is set to start on 1 June 2018, and the study 
will run until 31 May 2019. There will be a baseline assess-
ment and two follow-ups, at 3 and 6 months.
study population
Those subjects who meet the selection criteria and sign 
the informed consent after receiving information about 
the objectives and implementation of the study will take 
part.
Inclusion criteria: women between 50 and 64 years in 
postmenopause, defined by and checked against amenor-
rhoea during at least 12 consecutive months.
Exclusion criteria: a personal history of cardiovascular 
disease; personal history of diabetes mellitus, arterial 
hypertension or dyslipidaemia under pharmacological 
treatment; hypocaloric diets; clinically demonstrable 
neurological and/or neuropsychological disease; treat-
ment with hormone replacement therapy; intolerance 
and/or allergy to cocoa or any of the components of the 
supplement.
Participants will be selected using a consecutive 
sample of women who meet the selection criteria in the 
general practitioner surgeries of four urban primary care 
centres in Salamanca, from 1 June, 2018.
Patient and public involvement
Patients and the public were not involved in the design 
of this study or outcome measures. We hope that the 
results of the study will be disseminated through press 
releases and information-sharing meetings with the study 
participants.
sample size
The size of the sample has been estimated based on 
the potential modification of the main variable, systolic 
blood pressure (SBP). Given alpha and beta risks of 0.05 
and 0.20 respectively in bilateral contrast and an SD of 
5.8 mm Hg, 140 participants (70 per group) will be neces-
sary to detect a minimum difference of 2.9 mm Hg in the 
SBP between the two groups. A predicted drop-out rate of 
10% during follow-up has been taken into account. This 
estimate has considered the results obtained in a similar 
study in which a decrease in SBP of 6.5 was observed 
±5.8 mm Hg.14
randomisation
Participants will be assigned to the intervention group 
(IG) or control group (CG) at random. The allocation 
sequence will be generated by an independent researcher 
using the Epidat V.4.2 program46 before the inclusion of 
the first participant, using masked block randomisation. 
Patients will receive their randomisation number based on 
the order of their baseline evaluation visit and will remain 
hidden until the participants are assigned to each group. 
To ensure that the blinding is maintained, patients will be 
given clear instructions not to disclose which treatment 
they have been randomised to while being interviewed 
by the blind assessors. Information on treatment alloca-
tion will be stored in a secure locker in case of emergency 
unblinding.
Intervention
No type of intervention will be carried out with the CG 
participants.
IG participants will be given chocolate with 99% 
cocoa content and asked to eat 10 g daily for 6 months. 
According to the European Food Safety Authority, 10 g 
of high-flavanol dark chocolate consumed in the context 
of a balanced diet could help maintain endothelium-de-
pendent vasodilation.47 Participants will also be given 
instructions on eating and keeping the product, with the 
recommendations, for example, that the chocolate can 
be consumed in small pieces leaving them unmated in 
the mouth, without chewing them. Also, a series of recom-
mendations will be given addressing the organoleptic 
characteristics of the product, as well as the recommen-
dations of trying to consume the product at the same time 
or refrain from ingesting it dissolved in milk. Also, partici-
pants will be given a calendar on which to record the time 
it was eaten each day. This calendar will be returned to 
the researchers at each replenishment visit.
This amount of chocolate provides the following 
daily nutritional contribution: 59 kcal, 0.8 g of carbo-
hydrates, 1.5 g of protein, 5.1 g of fat, of which 3.1 g are 
saturated fats. The proportion of polyphenols per 10 g 
is 65.4 mg. The polyphenolic profile of this compound 
can be seen in table 1. On each visit, IG participants 
will receive the amount of chocolate they need until the 
Table 1 Polyphenols composition of 99% cocoa chocolate
Compounds Quantity
Protocatechuic acid (mg/g) 0.058±0.008
Procyanidin dimer (B3) (mg/g) 0.176±0.013
Catechin (mg/g) 1.035±0.105
Procyanidin dimer (B2) (mg/g) 1.440±0.055
Epicatechin (mg/g) 2.610±0.075
Procyanidin trimer (C1) (mg/g) 0.853±0.024
Procyanidin A hexoside (mg/g) 0.354±0.007
Quercetin glucoside (mg/g) 0.002±0.000
Quercetin arabinoside (mg/g) 0.003±0.001
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next replenishment visit. In addition to the baseline visit, 
there will be five replenishment visits in months 1, 2, 3 
(coinciding with the evaluation visit), 4 and 5. The sole 
purpose of the replenishment visits will be to supply the 
amount of chocolate needed until the next visit, without 
any other intervention being carried out.
Participants in both groups will be instructed to 
continue with the dietary pattern they usually follow, 
without changing their eating habits during the study 
period.
Procedures
For each participant a baseline visit and two follow-up 
visits at 3 and 6 months after the initial one are scheduled 
(figure 1). The IG will also make five replenishment visits, 
in months 1, 2, 3 (coinciding with the first follow-up visit), 
4 and 5. In the replenishment visits, participants will be 
given the amount of chocolate needed until the next visit 
and will hand in the calendar with the record of the choc-
olate eaten.
Primary and secondary endpoints
The primary variable will be the decrease in clinical 
blood pressure, measured with a digital sphygmoma-
nometer. Secondary variables will include vascular func-
tion, quality of life, cognitive performance and body 
composition.
All variables will be measured at 3 and 6 months after 
randomisation, except for cognitive performance and 
quality of life, which will be assessed only after 6 months.
blood pressure
Clinical systolic and diastolic blood pressure will be 
measured with a validated Omron M10-IT sphygmo-
manometer (Omron Healthcare, Kyoto, Japan). Three 
measurements will be taken in the dominant arm of the 
subject in a sitting position after at least 5 min of rest with 
an appropriately sized cuff, following the recommenda-
tions of the European Society of Hypertension.48 The 
average of the last two measurements will be recorded.
Vascular function
The Vasera VS-2000 device (Fukuda Denshi) will be used 
to measure the CAVI and the brachial-ankle pulse wave 
velocity (ba-PWV) at rest. CAVI is a good indicator of 
arterial stiffness, providing an accurate estimate of the 
degree of atherosclerosis without depending on blood 
pressure.49 CAVI ≥9 and ba-PWV ≥18.3 will be considered 
pathological.50 Pathological CAVI is representative of 
subclinical atherosclerosis.51
Cognitive performance
The instructions are presented visually at the start of the 
baseline measurement to ensure limiting a learning effect 
over the subsequent testing periods. Attention and execu-
tive functions: Trail Making Test A will be used to measure 
attention and Trail Making Test B for processing speed 
and executive functions.52
Immediate verbal memory will be assessed with the Rey 
Auditory Verbal Learning Test. The immediate recall of 
a list of 15 words is measured in three attempts, followed 
by delayed verbal memory through the free recall of the 
words learnt in the first part of the test after 10 min.53
Working memory will be assessed with the WAIS Digit 
Span Backward test.54
Phonological fluency will be explored by naming as 
many words as possible starting with different letters of 
the FAS Questionnaire in the space of 1 min.55
Categorical fluency measures verbal semantic fluency 
and will be assessed by naming as many animals as possible 
in 1 min.56
Quality of life
The quality of life linked to health will be assessed through 
the EuroQol 5-D questionnaire. We will use the adapted 
Spanish version of this questionnaire, which has been 
validated in the Spanish population.57 This questionnaire 
consists of three elements: the assessment by the individ-
uals of their state of health in level of severity by dimension 
(mobility, personal care, daily activities, pain/discomfort 
and anxiety/depression), the assessment of their state of 
health on an analogue visual scale and finally an index of 
social values obtained for each state of health generated 
by the instrument.
The quality of life will also be studied using the 
Cervantes Scale.58 This questionnaire is specifically 
designed for menopause and postmenopause and 
has been validated for Spanish women. Its 31 struc-
tured items cover the four dimensions of menopause: 
menopause and health, sexuality, psychic domain and 
relationships.
body composition
Body composition will be measured with the Inbody 
230 Monitor.59 This analyser provides data on fat mass 
and body fat percentage as principal outcomes and 
also skeletal muscle mass, total body water, fat-free 
mass, waist-hip ratio, basal metabolism and a segmental 
analysis.
Body weight will be measured twice with an electronic 
scale (Scale 7830, Soehnle Professional, Backnang, 
Germany) after proper calibration (accuracy ±0.1 kg). 
Height will be measured by recording the average of 
two readings rounded to the nearest centimetre using 
a stadiometer (Seca 222, Medical Scale and Measure-
ment System, Birmingham, UK). Both measurements 
will be made with the subject barefoot and wearing light 
clothing. BMI will be calculated by dividing weight (kg) by 
height squared (m2). Waist circumference will be assessed 
in accordance with the recommendations of the Spanish 
Society for the Study of Obesity60 and will be measured 
in duplicate before and after inhalation, using a flexible 
tape parallel to the floor, at the level of the midpoint 
between the lowest rib and the iliac crest, with the subject 
standing up and without clothes.
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other variables
Clinical and sociodemographic variables
At the baseline visit, information on clinical and socio-
demographic variables will also be collected via ques-
tions about age, marital status, educational level and 
occupation. The family history of cardiovascular disease 
and personal history of anxiety and depression, gesta-
tional diabetes, hypertension, dyslipidaemia and the 
prescribed pharmacological treatment (antiaggregants, 
anticoagulants, thyroid hormone treatment, anxiolytics) 
Figure 1 Study flow chart.
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will also be recorded, as well as the taking of non-steroidal 
anti-inflammatory drugs in the last two weeks.
In subsequent visits, personal histories of cardiovascular 
disease, diabetes mellitus, arterial hypertension or dyslip-
idaemia in treatment, as well as the prescribed pharma-
cological treatment (hypolipidaemic, antihypertensive, 
antidiabetic) will also be noted.
Evaluation of chocolate consumption and habitual diet
Chocolate consumption will be assessed at each evalua-
tion visit by a series of questions about the amount, type 
and frequency of consumption in the period between 
visits.
Nutritional habits will be assessed by a 24 hours log on 
three non-consecutive days prior to each visit.
Evaluation of other lifestyles
The use of tobacco will be assessed with a questionnaire 
on the personal history and pattern of smoking.
Alcohol use will be recorded with a questionnaire 
covering the previous seven days, which will include 
specific beverages and the amount by volume drunk of 
each.
Physical activity will be measured using the Interna-
tional Physical Activity Questionnaire in its short version 
and validated in Spanish.61 This questionnaire measures 
activity over the previous seven days, classifying the 
subjects according to three activity levels (low, moderate 
and high) with respect to three types of activities: walking, 
moderate-intensity activities and vigorous-intensity activi-
ties. The amount of physical exercise will be estimated in 
METs-minute/week.
Evaluation of laboratory variables
At baseline and follow-up visits at 6 months, we will measure 
plasma fasting glucose values (mg/dL), glycated haemo-
globin (%), total cholesterol (mg/dL), total triglycerides 
(mg/dL), high-density lipoprotein cholesterol (mg/dL), 
low-density lipoprotein cholesterol (mg/dL), creatinine 
(mg/L) and insulinaemia (mg/dL). Creatinine in urine 
(mg/dL) and microalbuminuria (mg/dL) will also be 
measured. Insulin resistance will be determined using the 
Homeostasis Model Assessment Insulin Resistance index 
estimated using the following equation: Fasting glucose 
(mmol/L)×insulin (mU/mL)/22.5.
The evaluation visits will be made in the morning 
between 08:00 and 10:00. Each participant will be 
informed prior to the visit to fast for at least 12 hours, 
having avoided during the 24 hours prior to visiting the 
consumption of polyphenol-rich foods, including cocoa, 
chocolate, apples and red wine as well as alcoholic drinks 
or the performance of the programmed physical activity. 
All evaluation visits, including blood pressure measure-
ments and evaluations of vascular function, will be carried 
out in a room with standardised lighting and tempera-
ture, recommending that patients attend the appoint-
ment with a prior rest of at least 8–10 hours.
Data collection procedure, data management and monitoring
Data collection of the baseline and follow-up evaluation 
visits at 3 and 6 months will be carried out by a nurse 
specifically trained to do so. The intervention visit after the 
baseline evaluation will be carried out by another nurse, 
different from the one who performs the data collection. 
Each participant will have a unique identification code 
within the study. All measurements will be compiled in a 
data collection notebook and kept in a secure place that 
will remain closed within the health centre. A database 
will be created in SPSS to which only the members of the 
research team and the people related to the statistical 
analyses will have access. The principal investigator or a 
person designated for this purpose will perform a weekly 
process of monitoring the study, taking into account the 
inclusion of patients, cleaning and debugging of data-
bases, and adaptation of the procedures to the protocol.
blinding strategy
Due to the nature of the intervention itself, the partici-
pants and the person responsible for delivering the choc-
olate to IG participants cannot be blinded. However, the 
person responsible for carrying out the study measure-
ments at each visit and for the statistical analysis will be 
blind to the intervention.
statistical analysis
General analysis
Results for the quantitative variables will be expressed 
by mean±SD or by frequency distribution in the case of 
qualitative variables. The normality of the variables will 
be assessed using the Kolmogorov-Smirnov test. In cases 
where a normal distribution cannot be assumed, the 
corresponding non-parametric tests will be applied. The 
association between independent qualitative variables will 
be analysed using the χ2 test or Fisher’s exact test. The 
means between the two groups will be compared using 
the Student’s t-test or the Mann-Whitney U test, and the 
Pearson or Spearman correlation coefficients will be 
calculated to analyse the relationship between quantita-
tive variables.
The analysis of the results for the main variable and 
the secondary variables will be carried out by intention 
to treat. Also, a secondary analysis will be made, taking 
into account chocolate intake adherence (<50% days 
and >50% days) and other relevant subgroups in rela-
tion to their physical activity or previous chocolate 
consumption.
All analyses will be performed using SPSS V.23.0 (IBM) 
and an alpha risk of 0.05 will be set as the limit of statis-
tical significance.
Analysis of the intervention’s effect on primary and secondary 
outcomes
To analyse the changes at 3 and 6 months from baseline 
in the primary outcome (blood pressure) and in the 
secondary outcomes within the same group, the Student’s 
t-test for paired data or the Wilcoxon test will be used. 
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The McNemar test will be applied with quantitative or 
dichotomous variables.
Effects of the intervention will be analysed in a compar-
ison of the changes in blood pressure and the secondary 
variables between the IG and the CG using analysis of 
covariance and adjusting for possible confounders, for 
example, smoking status. Effects of the intervention 
during follow-up will be studied with an analysis of the 
variance of repeated measures.
Analysis by subgroups
The effect of the intervention could be influenced by age, 
sociocultural level and adherence to the study’s choco-
late intake. The same analyses described above will be 
performed for each of the subgroups above.
Secondary analyses
A multivariate multiple regression analysis will be 
performed to identify the variables with the greatest influ-
ence on blood pressure changes and the secondary vari-
ables analysed.
Methodological limitations
Due to the nature of the intervention, the participating 
subjects cannot be blinded. However, the researcher 
who analyses the data and the person who makes the 
measurements during follow-up visits will be blinded with 
respect to the group to which the participants belong. 
The smoking status in the 12 months prior to the time of 
inclusion could influence the outcome measures related 
to vascular function and blood pressure; therefore, 
although these participants will not be excluded, this 
aspect will be controlled in the statistical analysis. Assess-
ment of the quality of life and lifestyles will be carried out 
through self-reported data; however, previously validated 
instruments will be used to obtain these. To make compli-
ance with the intervention in the IG easier, IG participants 
will be provided with instructions on eating the chocolate 
and a calendar to record each intake.
EthICs And dIssEMInAtIon
Ethical considerations
The study was approved by the Clinical Research Ethics 
Committee of the Salamanca Health Area (‘CREC of 
Health Area of Salamanca’) in February 2018. A SPIRIT 
checklist is available for this protocol. The clinical trial 
has been registered at  ClinicalTrials. gov with the identi-
fier NCT03492983.
Participants must provide informed consent in accor-
dance with the Declaration of Helsinki. Subjects will be 
informed of the objectives of the project and the risks and 
benefits of the explorations to be carried out, including 
sample collection. None of the tests will pose risks that 
could endanger the lives of participants. Confidentiality 
of participant data will be guaranteed at all times in accor-
dance with the provisions of the Organic Law on the 
Protection of Personal Data (15/1999 of 13 December 
LOPD), and under the conditions established by Law 
14/2007 of biomedical research.
dissemination plan
The research group plans to achieve rapid and wide-
spread dissemination of results to ensure maximum visi-
bility of this study. To this end, the results of the study 
will be published in open-access scientific journals with 
peer review. At least one publication of the main results 
and others with the secondary results are planned. This 
will be complemented by the presentation of the results 
of the study at relevant scientific conferences and semi-
nars of national and international scope. Also, a doctoral 
thesis based on this project will be prepared. Appropriate 
dissemination will likewise be carried out through social 
networks and other media. Moreover, given the involve-
ment of a commercial product, the transfer to clin-
ical practice is expected to be rapid if the results are as 
expected.
dIsCussIon
In recent years, there has been an increase in attention to 
polyphenols and their beneficial effects on health, with 
numerous studies being carried out to assess this.19 21 Simi-
larly, the therapeutic use of these compounds has been 
suggested for certain diseases or population groups.36 62 
The menopause increases the risk of developing cardio-
vascular disease compared with the previous period.45 
However, we have not found any study that assesses the 
effect of adding commercially available chocolate high in 
cocoa content to the usual diet in this population. Simi-
larly, no studies have been found that evaluate the effects 
on cognitive performance, quality of life and body compo-
sition of adding commercial chocolate with high cocoa 
content to the usual diet in postmenopausal women.
This work will provide novel data helpful for the devel-
opment of strategies in the nutritional education of 
particularly vulnerable populations, given their high risk 
of developing cardiovascular disease, including non-phar-
macological therapies and strategies that employ lifestyle 
modification. This intervention might also have implica-
tions for the preparation of recommendations in clinical 
practice guidelines and quality improvement programmes 
aimed at the care of postmenopausal women.
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